Merck, Serum Institute sign pneumoccocal vaccine deal for developing countries
This article was originally published in Scrip
Executive Summary
Merck and the Serum Institute of India Ltd have agreed to collaborate in order to bring a pneumococcal conjugate vaccine to emerging and developing world countries. The deal includes a product advisory committee that will oversee the vaccine development and work towards World Health Organisation prequalification of the product. Financial details remain confidential.